Blanchard Cheryl R 4

4 · Anika Therapeutics, Inc. · Filed Mar 11, 2025

Form 4

Period: 2025-03-10

DirectorPresident, CEO, Director

Transactions

Tax Payment
Common Stock
2025-03-10$16.62/sh−5,871$97,576→ 166,955 total
Exercise/Conversion
Common Stock
2025-03-10+20,002→ 172,826 total
Exercise/Conversion
Restricted Stock Unit
2025-03-10−20,002→ 20,001 total
Exercise: $0.00→ Common Stock (20,002 underlying)

Holdings

Footnotes (6)

[F1]Reflects the second vesting installment of RSUs granted on March 9, 2023.
[F2]Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2024 and 330 shares purchased on November 14, 2024.
[F3]Reflects an aggregate of 5,871 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2025.
[F4]Reflects the closing price of ANIK common stock on March 7, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations.
[F5]Consists of shares transferred by Dr. Blanchard to The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which Dr. Blanchard is a beneficiary and the sole trustee.
[F6]Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024.

Documents

1 file